Advertisement

  • Loading metrics

Open Access

Correction

Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice

  • Nicole Caduff,
  • Donal McHugh,
  • Anita Murer,
  • Patrick Rämer,
  • Ana Raykova,
  • Vanessa Landtwing,
  • Lisa Rieble,
  • Christian W. Keller,
  • Michael Prummer,
  • Laurent Hoffmann,
  • Janice K. P. Lam,
  • Alan K. S. Chiang,
  • Friedrich Raulf,
  • Tarik Azzi,
  • Christoph Berger,
  • Tina Rubic-Schneider,
  • Elisabetta Traggiai,
  • Jan D. Lünemann,
  • Michael Kammüller,
  •  [ ... ],
  • Christian Münz
  • [ view all ]
  • [ view less ]
  • Article
  • Metrics
  • Comments
  • Media Coverage

The following information is missing from the Funding statement: AKSC was supported by a HMRF grant (18170462).

Reference

  1. 1. Caduff N, McHugh D, Murer A, Rämer P, Raykova A, Landtwing V, et al. (2020) Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. PLoS Pathog 16(4): e1008477. https://doi.org/10.1371/journal.ppat.1008477 pmid:32251475

Citation: Caduff N, McHugh D, Murer A, Rämer P, Raykova A, Landtwing V, et al. (2020) Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice. PLoS Pathog 16(12): e1009167. https://doi.org/10.1371/journal.ppat.1009167

Published: December 21, 2020

Copyright: © 2020 Caduff et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.